These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15001208)

  • 1. Spironolactone for the treatment of isolated systolic hypertension.
    Yarows SA
    Am J Hypertens; 2004 Mar; 17(3):284. PubMed ID: 15001208
    [No Abstract]   [Full Text] [Related]  

  • 2. Aldosterone antagonist therapy in resistant hypertension.
    Zannad F
    J Hypertens; 2007 Apr; 25(4):747-50. PubMed ID: 17351364
    [No Abstract]   [Full Text] [Related]  

  • 3. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone and ACE inhibition in chronic renal failure.
    Epstein FH
    N Engl J Med; 2002 Feb; 346(6):456-7. PubMed ID: 11832542
    [No Abstract]   [Full Text] [Related]  

  • 5. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
    Ogawa S; Takeuchi K; Mori T; Nako K; Ito S
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):477-9. PubMed ID: 16700881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma.
    Zarnegar R; Lee J; Brunaud L; Lindsay S; Kebebew E; Clark OH; Duh QY
    Surgery; 2007 Dec; 142(6):921-9; discussion 921-9. PubMed ID: 18063077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
    Mahmud A; Feely J
    Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding low-dose spironolactone to multidrug regimens for resistant hypertension.
    Berecek KH; Farag A; Bahtiyar G; Rothman J; McFarlane SI
    Curr Hypertens Rep; 2004 Jun; 6(3):211-2. PubMed ID: 15128473
    [No Abstract]   [Full Text] [Related]  

  • 10. Spironolactone management of resistant hypertension.
    Marrs JC
    Ann Pharmacother; 2010 Nov; 44(11):1762-9. PubMed ID: 20978214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new class of potent antihypertensive agents. Especially systolic pressure is significantly reduced].
    MMW Fortschr Med; 1999 Nov; 141(47):8. PubMed ID: 10912157
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
    Preston RA; Norris PM; Alonso AB; Ni P; Hanes V; Karara AH
    Menopause; 2007; 14(3 Pt 1):408-14. PubMed ID: 17224857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and pharmacologic approach to patients with resistant hypertension.
    Adams M; Bellone JM; Wright BM; Rutecki GW
    Postgrad Med; 2012 Jan; 124(1):74-82. PubMed ID: 22314117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension.
    Sharabi Y; Adler E; Shamis A; Nussinovitch N; Markovitz A; Grossman E
    Am J Hypertens; 2006 Jul; 19(7):750-5. PubMed ID: 16814132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary hyperaldosteronism in a patient with end-stage renal disease.
    Kazory A; Weiner ID
    Nephrol Dial Transplant; 2007 Mar; 22(3):917-9. PubMed ID: 17127694
    [No Abstract]   [Full Text] [Related]  

  • 16. Aliskiren combined with losartan in diabetes and nephropathy.
    Lindner T
    N Engl J Med; 2008 Sep; 359(10):1068-9; author reply 1069-70. PubMed ID: 18777612
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hypertension in patients with diabetes].
    Poulsen PL; Hansen KW; Gaede PH; Rossing P
    Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion.
    Bubbar CD; Blackburn DF; Wilson MP; Wilson TW
    Ann Pharmacother; 2007 Jan; 41(1):129-32. PubMed ID: 17179189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
    Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of aldosterone antagonists in resistant hypertension.
    Calhoun DA
    Prog Cardiovasc Dis; 2006; 48(6):387-96. PubMed ID: 16714158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.